# Relative Bioavailability Study of GSK1265744 Formulations

> **NCT01648257** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 18 (actual)

## Conditions studied

- Infections, Human Immunodeficiency Virus and Hepatitis

## Interventions

- **DRUG:** GSK1265744 Na Salt Tablets
- **DRUG:** GSK1265744 Free Acid Nanomilled Capsules
- **DRUG:** GSK1265744 Free Acid Micronized Capsules

## Key facts

- **NCT ID:** NCT01648257
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01648257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01648257, "Relative Bioavailability Study of GSK1265744 Formulations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01648257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*